# C_2022218EN.01001301.xml

| 2.6.2022 | EN | Official Journal of the European Union | C 218/13 |
| --- | --- | --- | --- |

2.6.2022

EN

Official Journal of the European Union

C 218/13

---

Prior notification of a concentration

(Case M.10635 - CVC / HTB / FL)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 218/08)

1.

This notification concerns the following undertakings:

| — | CVC Capital Partners SICAV-FIS S.A. (‘CVC’, Luxembourg), |
| --- | --- |

—

CVC Capital Partners SICAV-FIS S.A. (‘CVC’, Luxembourg),

| — | Hartenberg Holding, s.r.o. (‘HTB’, Czech Republic), |
| --- | --- |

—

Hartenberg Holding, s.r.o. (‘HTB’, Czech Republic),

| — | FutureLife, a.s. (‘FL’, Czech Republic), controlled by HTB. |
| --- | --- |

—

FutureLife, a.s. (‘FL’, Czech Republic), controlled by HTB.

CVC and HTB will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of FL.

The concentration is accomplished by way of purchase of shares.

2.

| — | CVC, its subsidiaries and affiliated companies are privately owned entities whose activities include providing investment advice to and/or managing investments on behalf of certain investment funds and platforms. One of CVC’s portfolio companies, Mehiläinen, offers In-Vitro-Fertilization (‘IVF’) treatments in clinics in Finland. |
| --- | --- |

—

CVC, its subsidiaries and affiliated companies are privately owned entities whose activities include providing investment advice to and/or managing investments on behalf of certain investment funds and platforms. One of CVC’s portfolio companies, Mehiläinen, offers In-Vitro-Fertilization (‘IVF’) treatments in clinics in Finland.

| — | HTB is a company focused on investments in assets in the Central European Region, primarily Czech Republic, Slovakia and Poland, and is the current sole controlling shareholder of FL. |
| --- | --- |

—

HTB is a company focused on investments in assets in the Central European Region, primarily Czech Republic, Slovakia and Poland, and is the current sole controlling shareholder of FL.

| — | FL is active in the provision of reproductive medicine in various countries across Europe, in particular IVF treatment and ancillary services. FL’s business in Finland and Estonia will not form part of the proposed concentration, and will be transferred to, and remain solely controlled by, HTB. |
| --- | --- |

—

FL is active in the provision of reproductive medicine in various countries across Europe, in particular IVF treatment and ancillary services. FL’s business in Finland and Estonia will not form part of the proposed concentration, and will be transferred to, and remain solely controlled by, HTB.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10635 – CVC / HTB / FL

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---